Heart failure & cardiomyopathiesDiagnostic or prognostic study
Diagnostic Performance of the Mayo ATTR-CM Score in Diverse Populations
- validation study
- two complementary cohorts
Authors' conclusion
The Mayo ATTR-CM score demonstrates strong, consistent performance across diverse populations, including women, Black, and Hispanic individuals, and those with reduced EF, and outperforms the AMY score. Its reliance on routinely available clinical and echocardiographic data supports automated implementation and may facilitate earlier detection of ATTR-CM.
Study context
- Population
- Patients referred for cardiac amyloid radionuclide imaging at Mayo Clinic and Black or Caribbean Hispanic community-based individuals (SCAN-MP)Mayo Clinic cardiac amyloid radionuclide imaging referral cohort 1,553 · SCAN-MP 646
- Comparison
- Mayo ATTR-CM score vs AMY score for discrimination of ATTR-CM
Performance
As reported in the abstract
Discrimination for ATTR-CM (AUC)
| Test or model | Mayo cohort | SCAN-MP |
|---|---|---|
| Mayo ATTR-CM score | 0.86; 95% CI: 0.84-0.88 | 0.81; 95% CI: 0.75-0.87 |
| AMY | 0.67; 95% CI: 0.64-0.70 | 0.70; 95% CI: 0.62-0.78 |
- Mayo ATTR-CM score vs AMY: DeLong P < 0.001 for both — superior discrimination in both cohorts
Further findings
Performance among individuals with EF <40% and among women
- Performance remained robust among individuals with EF <40% and among women
Sensitivity of AMY score
- The AMY score showed lower sensitivity across cohorts
Probability of ATTR-CM among individuals exceeding score cutoffs
- Mayo cohort
- ∼1 in 2
- SCAN-MP
- ∼1 in 6
Original publication
Diagnostic Performance of the Mayo ATTR-CM Score in Diverse Populations. JACC Adv. doi:10.1016/j.jacadv.2026.102843
Summarised from the published abstract; every number is checked against it